Amani Nabil Shafik

Prof. Dr. Amani Nabil Shafik

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
ASAmani Nabil Shafik
Amani Nabil Shafik

1 January 2019 in Brain Research Bulletin
Verified
Journal Article
Closed access
VFVeronia Fawzy Fahim
Veronia Fawzy Fahim
WWWalaa Wadie
Walaa Wadie
ASAmani Nabil Shafik
Amani Nabil Shafik
MAMagdy Ishak Attallah
Magdy Ishak Attallah

1 June 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ASAmani Nabil Shafik
Amani Nabil Shafik

30 September 2011 in Arab Journal of Gastroenterology
Verified
Journal Article
Closed access
ASAmani Nabil Shafik
Amani Nabil Shafik
MKMostafa M. Khodeir
Mostafa M. Khodeir
NGNadia A. Gouda
Nadia A. Gouda
MMMohamed E. Mahmoud
Mohamed E. Mahmoud

1 June 2018 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
ASAmani Nabil Shafik
Amani Nabil Shafik
MKMahmoud A. Khattab
Mahmoud A. Khattab
AOAhmed H. Osman
Ahmed H. Osman

24 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
ASAmani Nabil Shafik
Amani Nabil Shafik
VFVeronia Fawzy Fahim
Veronia Fawzy Fahim
FIFady Fady Iskander
Fady Fady Iskander
HEHassan Elsayegh
Hassan Elsayegh
HSHani Serag
Hani Serag
Hanaa SallamHanaa Sallam
Hanaa Sallam
This review provides a comprehensive overview of the complex and dynamic bacterial composition of the human gastrointestinal (GI) microbiota and explores its integral role in the microbiome–gut–brain axis. It discusses the physiological and molecular pathways through which the gut microbiota communicates with the central nervous system, highlighting key barriers that can impede effective signaling along this axis. The review also delves into the influence of microbiota on brain health, including cognitive function, mood regulation, and neuroinflammation. It considers how disruptions in this system—known as dysbiosis—can contribute to metabolic and neurological dysfunction. The central focus of the article is the role of the commonly prescribed antidiabetic drug metformin, not only in regulating glucose metabolism but also in its emerging potential to beneficially modulate the gut microbiome. By doing so, metformin may indirectly support improved brain health. Ultimately, the article seeks to inform both healthcare practitioners and patients about the promising therapeutic implications of microbiome-targeted strategies, particularly metformin, in promoting cognitive and neurological well-being.